Mumbai, Nov. 7 -- Cohance Lifesciences announced that United States Food and Drug Administration (USFDA) has issued the Establishment Inspection Report (EIR) in respect of the Company's manufacturing facility located at Pashamylaram, Hyderabad and has classified the inspection outcome as Voluntary Action Indicated (VAI).

Published by HT Digital Content Services with permission from Capital Market....